Taisho
is a world-class leading company in the field of OTC medicines, marketing a
variety of products on a global scale. Taisho has made concerted efforts to
promote its Lipovitan D nutrient drink overseas. Lipovitan began its journey
overseas in 1963, and is now manufactured and sold by subsidiaries located
in Hong Kong, Taiwan, Malaysia, the Philippines, Indonesia, Thailand, Vietnam,
China, Australia, the United States and the United Kingdom. The Company is
particularly strengthening sales promotion activities in the huge market of
more than 1.2 billion people in China through bases in Shanghai, Beijing and
Guangzhou. In 1998, Taisho began selling LIBOGEN (Lipovitan) in China. We also
launched the nutrient drink Libaojian Yirenzhuang (Lipovitan Alfe), targeting
women who are active socially in China, which is experiencing sharp economic
growth. In 1991, we took our first steps in the European market, and Taisho
Pharmaceutical (Europe) Ltd. was established in London in 1998 as a base for
business expansion and to oversee our operations throughout the continent.
In the prescription drugs markets, Taisho sells a popular macrolide antibiotic agent Clarith through Abbott Laboratories of the United States in approximately 90 countries around the world. In collaboration with overseas companies and the introduction of new technologies, Taisho aims to be a global prescription pharmaceutical manufacturer that provides innovative products to people around the world.
Taisho
is a world-class leading company in the field of OTC medicines, marketing a
variety of products on a global scale. Taisho has made concerted efforts to
promote its Lipovitan D nutrient drink overseas. Lipovitan began its journey
overseas in 1963, and is now manufactured and sold by subsidiaries located
in Hong Kong, Taiwan, Malaysia, the Philippines, Indonesia, Thailand, Vietnam,
China, Australia, the United States and the United Kingdom. The Company is
particularly strengthening sales promotion activities in the huge market of
more than 1.2 billion people in China through bases in Shanghai, Beijing and
Guangzhou. In 1998, Taisho began selling LIBOGEN (Lipovitan) in China. We also
launched the nutrient drink Libaojian Yirenzhuang (Lipovitan Alfe), targeting
women who are active socially in China, which is experiencing sharp economic
growth. In 1991, we took our first steps in the European market, and Taisho
Pharmaceutical (Europe) Ltd. was established in London in 1998 as a base for
business expansion and to oversee our operations throughout the continent.
In the prescription drugs markets, Taisho sells a popular macrolide antibiotic agent Clarith through Abbott Laboratories of the United States in approximately 90 countries around the world. In collaboration with overseas companies and the introduction of new technologies, Taisho aims to be a global prescription pharmaceutical manufacturer that provides innovative products to people around the world.